Accendra Health Inc/Va/
ACH NYSE· Wholesale-Medical, Dental & Hospital Equipment & Supplies
Last close · Oct 26, 2026
$0.20
KIRA · Stoqly’s AI analyst, in plain words
- Accendra Health Inc/Va/ had $2.8B of revenue in fiscal 2025, up 3.1% on the year before. Over five years, revenue changed −20.1% a year on average.
- Its operating margin was 1.0%, up 9.1 pts: of every 100 in sales, about 1 is left after running the business.
- Accendra Health Inc/Va/ lost $1.1B in fiscal 2025.
- Free cash flow was −$293M in fiscal 2025, −10.6% of revenue.
- Accendra Health Inc/Va/ returned $10.2M to shareholders in fiscal 2025. The diluted share count rose 0.2%.
- Accendra Health Inc/Va/ owes $1.8B more than it holds in cash, about 7.3 years of operating profit.
Market cap
$15.6M
P/E
—
Revenue
$2.8B
Net income
−$1.1B
Free cash flow
−$293M
Operating margin
1.0%
Accendra Health Inc/Va/ in 30 seconds · fiscal 2025
Are sales growing?
+3.1%
Only a little. Sales grew 3.1% last year.
Does it make a profit?
−39.8%
No. It lost money last year.
Does profit turn into cash?
−10.6%
No. It spent more cash than it brought in.
Is debt under control?
7.3x
Heavy. Repaying its debt would take 7.3 years of operating profit.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Accendra Health Inc/Va/ does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 20, 2026
- Legal name
- ACCENDRA HEALTH INC/VA/
- CIK
- 0000075252
Accendra Health Inc/Va/ · ACH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $9.8B | $10.0B | $2.6B | $2.7B | $2.8B |
| Revenue growth | 15.4% | 1.7% | −74.4% | 5.0% | 3.1% |
| Gross margin | 15.5% | 18.3% | 83.3% | 82.8% | 46.7% |
| Operating margin | 3.8% | 1.4% | 5.2% | −8.1% | 1.0% |
| Net income | $222M | $22.4M | −$41.3M | −$363M | −$1.1B |
| Net margin | 2.3% | 0.2% | −1.6% | −13.5% | −39.8% |
| Diluted EPS | $2.94 | $0.29 | −$0.53 | −$4.73 | −$14.31 |
| Cash | |||||
| Cash from operations | $124M | $325M | $741M | $161M | −$102M |
| Capital expenditure | $41.0M | $158M | $172M | $170M | $191M |
| Free cash flow | $83.2M | $167M | $568M | −$8.8M | −$293M |
| FCF margin | 0.9% | 1.7% | 22.3% | −0.3% | −10.6% |
| Dividends paid | $0.7M | $0.0M | $0.0M | — | — |
| Share buybacks | — | — | — | — | $10.2M |
| Share count change | 18.9% | 1.0% | 1.5% | −0.8% | 0.2% |
| Debt and strength | |||||
| Cash and short-term investments | $55.7M | $69.5M | $243M | $27.6M | $282M |
| Debt incl. finance leases | $961M | $2.5B | $2.1B | $1.9B | $2.0B |
| Shareholders' equity | $939M | $967M | $945M | $586M | −$461M |
| Net debt / EBITDA | 2.0x | 6.6x | 5.4x | — | 7.3x |
| Current ratio | 1.7x | 1.5x | 1.1x | 1.1x | 0.6x |
| Interest coverage | 7.7x | 1.1x | 1.1x | −2.0x | 0.3x |
| Returns and quality | |||||
| Return on capital | 16.1% | 4.2% | 3.1% | −7.2% | 1.7% |
| Return on equity | 26.9% | 2.4% | −4.3% | −47.4% | −1,755.6% |
| Return on tangible equity | 65.4% | — | — | — | — |
| Piotroski F-score | 7 | 4 | 4 | 5 | 2 |
| Altman Z'' | 3.3 | 1.5 | 0.9 | 0.1 | −2.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Accendra Health Inc/Va/ · ACH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.20 a share, the company is worth $15.6M.
Source: SEC EDGAR XBRL filings (CIK 0000075252). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.